13-valent pneumococcal vaccine: all 128 studies that test it

Page 1 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsRecruitingNCT07286370Phase 2
• Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a LymphomaRecruitingNCT04460235Phase 4
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedNCT05412030Phase 2Results posted
• A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSISCompletedNCT05372575Not applicableResults posted
• A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in IndiaCompletedNCT05329259Phase 4Results posted
• Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedNCT04080531Phase 4Results posted
• A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthCompletedNCT03819049Phase 1/2Results posted
• Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In IndiaCompletedNCT03777865Phase 4Results posted
• Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedNCT03691610Phase 3Results posted
• A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedNCT03620162Phase 3Results posted
• A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young ChildrenCompletedNCT03574389Phase 3Results posted
• A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.CompletedNCT03571607Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy InfantsTerminatedNCT03550313Phase 2Results posted
• Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In IndiaCompletedNCT03548337Phase 4Results posted
• Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood VaccinesCompletedNCT03530124Phase 4Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and OlderCompletedNCT03439657Phase 3Results posted
• Pneumococcal Vaccines in Patients With AsthmaCompletedNCT03260790Phase 4Results posted
• This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized VaccineCompletedNCT03207750Phase 3Results posted
• Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 3Results posted
• Fever After Simultaneous Versus Sequential Vaccination in Young ChildrenCompletedNCT03165981Phase 4Results posted
• Genomics and Epigenomics of the Elderly Response to Pneumococcal VaccinesCompletedNCT03104075Phase 4Results posted
• Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary PathologyCompletedNCT02787863Phase 4Results posted
• Vaccinating Children After ChemotherapyCompletedNCT02447718Phase 4Results posted
• Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)CompletedNCT02225587Phase 3Results posted
• Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.CompletedNCT02124161Phase 4Results posted
• 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in IndiaCompletedNCT02034877Phase 4Results posted
• Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal DiseaseCompletedNCT01974817Phase 4Results posted
• 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.CompletedNCT01964716Phase 3Results posted
• Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™VaccineCompletedNCT01939158Phase 3Results posted
• Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous TransplantCompletedNCT01852591Not applicableResults posted
• A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide VaccineCompletedNCT01654263Phase 2Results posted
• A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and OlderCompletedNCT01646398Phase 3Results posted
• Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™CompletedNCT01641133Phase 3Results posted
• 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in MexicoCompletedNCT01432262Phase 3Results posted
• Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant CyclophosphamideTerminatedNCT01282216Phase 2Results posted
• Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese InfantsCompletedNCT01200368Phase 3Results posted
• Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.CompletedNCT01193335Phase 4Results posted
• Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.CompletedNCT01026038Phase 3Results posted
• Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant RecipientsCompletedNCT00980655Phase 3Results posted
• Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPSCompletedNCT00963235Phase 3Results posted
• Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal VaccineCompletedNCT00962780Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell DiseaseCompletedNCT00918580Phase 3Results posted
• Immune Response In Children Revaccinated With Pneumococcal Conjugate VaccineCompletedNCT00853749Phase 3Results posted
• Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive CohortCompletedNCT00824850Phase 2Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy ChildrenCompletedNCT00824655Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 YearsCompletedNCT00761631Phase 3Results posted
• Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in AdultsCompletedNCT00744263Phase 4Results posted
• Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.CompletedNCT00743652Phase 3Results posted
• Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in MexicoCompletedNCT00708682Phase 3Results posted
• Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In KoreaCompletedNCT00689351Phase 2Results posted
• Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in TaiwanCompletedNCT00688870Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in BrazilCompletedNCT00676091Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese InfantsCompletedNCT00574795Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 YearsCompletedNCT00562354Phase 3Results posted
• Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)CompletedNCT00546572Phase 3Results posted
• Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza VaccineCompletedNCT00521586Phase 3Results posted
• Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal ColonizationCompletedNCT00508742Phase 3Results posted
• Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly SubjectsCompletedNCT00500357Phase 3Results posted
• Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly SubjectsCompletedNCT00500266Phase 3Results posted
• Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in AdultsCompletedNCT00492557Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy InfantsCompletedNCT00475033Phase 3Results posted
• Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsCompletedNCT00474539Phase 3Results posted
• Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedNCT00464945Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in IndiaCompletedNCT00452790Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and ChildrenCompletedNCT00452452Phase 3Results posted
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy InfantsCompletedNCT00444457Phase 3Results posted
• Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in AdultsCompletedNCT00427895Phase 3Results posted
• Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedNCT00384059Phase 3Results posted
• Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate VaccineCompletedNCT00373958Phase 3Results posted
• Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.CompletedNCT00368966Phase 3Results posted
• Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedNCT00366899Phase 3Results posted
• Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedNCT00366678Phase 3Results posted
• Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.CompletedNCT00366340Phase 3Results posted
• Study Evaluating Pneumococcal Vaccine in Healthy InfantsCompletedNCT00205803Phase 1/2Results posted
• A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsCompletedNCT07019909Phase 1
• Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 YearsCompletedNCT06675032Phase 1
• Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingNCT06647407Phase 1/2
• A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 YearsCompletedNCT06210737Phase 4
• Phase I Clinical Trial of a Candidate PCV13 in Healthy PeopleStatus unknownNCT05602480Phase 1
• PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)Status unknownNCT04974294Phase 4
• Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.CompletedNCT03873727Phase 2
• Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected AdultsCompletedNCT03838497Phase 4
• Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic DiseaseCompletedNCT03762824Phase 4
• Impact of HIV-1 and Aging on Mucosal Vaccine ResponsesActive, not recruitingNCT03729778Early Phase 1
• Pneumococcal Vaccination of Multiple Myeloma Patients on Novel AgentsCompletedNCT03619252Phase 4
• Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis SurvivorsCompletedNCT03565159Phase 4
• Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate VaccineCompletedNCT03552445Phase 4
• The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan InfantsCompletedNCT03489018Phase 4
• CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming StudyCompletedNCT03384589Phase 2/3
• Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected PatientsStatus unknownNCT03041051Phase 4
• Immune Response to Pneumococcal Vaccination in Aging HIV Positive AdultsCompletedNCT03039491Early Phase 1
• Reduced PCV Dosing Schedules in South African InfantsCompletedNCT02943902Phase 3
• Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)CompletedNCT02736240Phase 3
• Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled TrialCompletedNCT02640703Phase 3
• Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody LevelsCompletedNCT02637583Phase 4
• Protecting From Pneumococcus in Early Life (The PROPEL Trial)Status unknownNCT02628886Phase 3
• Influenza Vaccine and Pneumococcal VaccineCompletedNCT02582047Phase 4
• Pneumonia Vaccine in Aging HIV Positive IndividualsCompletedNCT02558751Early Phase 1
• A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy InfantsCompletedNCT02494999Phase 3
• 13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis PatientsCompletedNCT02492438Phase 4

← 13-valent pneumococcal vaccine overview